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Abstract
In this paper we review an approach to estimating the causal effect of a time-
varying treatment on time to some event of interest. This approach is designed
for the situation where the treatment may have been repeatedly adapted to patient
characteristics, which themselves may also be time-dependent. In this situation the
effect of the treatment cannot simply be estimated by conditioning on the patient
characteristics, as these may themselves be indicators of the treatment effect. This
so-called time-dependent confounding is typical in observational studies. We discuss
a new class of failure time models, structural nested failure time models, which can be
used to estimate the causal effect of a time-varying treatment, and present methods
for estimating and testing the parameters of these models.
1 Introduction
This paper offers a new approach to estimating, from observational data, the causal effect
of a time-dependent treatment on time to an event of interest in the presence of time-
dependent confounding variables. This approach is based on a new class of failure time
models, the structural nested failure time models (SNFTM). The primary goal of this paper
is to motivate the need for structural nested failure time models. To achieve this goal in the
most straightforward manner, we shall assume that the event times are observed without
censoring, and that there is no missing or misclassified data. Additional complications that
arise when these assumptions are not satisfied are discussed in Robins et al. (1992) and
Robins (1993).
The approach using SNTFMs will be useful in any observational study in which there
exist time-dependent risk factors that are also predictive for subsequent exposure to the
treatment under study, i.e. in any study where there are time-dependent covariates that
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correlate with the final outcome of the treatment, but also with the amount or type of
treatment over time. This situation arises in any observational study in which there is
“treatment by indication”, i.e. the treatment is not predetermined by the investigator,
but adapted to the current condition of the patient. The problem then is to distinguish
between treatment effect and selection bias (i.e. confounding). For example, in an obser-
vational study for the effect of AZT treatment on HIV-infected subjects, subjects with low
CD4 lymphocyte counts at a given time are subsequently at increased risk of developing
AIDS and are for that reason more likely to be treated with AZT. Thus the covariate
variables “low CD4-count” is a risk factor for AIDS, but is also a predictor of subsequent
treatment with AZT. The problem is then to isolate the effect of AZT treatment as given
according to a predetermined plan (which may take into account covariates) from the con-
founding effect of CD4-count. As a second example, many physicians withdraw women
from exogenous estrogens at the time they develop an elevated blood cholesterol, since
both exogenous estrogens and elevated blood cholesterol are considered possible cardiac
risk factors. Therefore, in a study of the effect of postmenopausal estrogen on cardiac
mortality, the covariate variables “cholesterol level” is a predictor of subsequent exposure
to estrogens, but also correlates with the outcome “cardiac mortality”. As a third example,
in observational studies of the efficacy of cervical cancer screening on mortality, women
who have had operative removal of their cervix due to invasive disease are no longer at
risk for further screening (i.e. exposure), but are at increased risk for death. Therefore, the
covariate, “operative removal of the cervix”, is an independent risk factor for death, but
also a predictor of subsequent exposure. As a final epidemiologic example, in occupational
mortality studies, unhealthy workers who terminate employment early are at increased
risk of death compared to other workers and receive no further exposure to the chemical
agent under study. Therefore, the time-dependent covariate “employment status” is an
independent risk factor for death, and a predictor of exposure to the study agent.
Epidemiologists refer to the covariates in the preceding examples as “time-dependent
confounders”. It may be important to analyze the data from any of the above studies using
the approach presented in this paper.
For pedagogic purposes, we shall illustrate our models and assumptions throughout the
paper by the problem of estimating, from data obtained in an observational study, the effect
of treatment with the drug AZT on time to clinical AIDS in asymptomatic subjects with
newly diagnosed human immunodeficiency virus (HIV) infection. We shall suppose that
measurements on current AZT dosage as well as on various time-dependent covariates, such
as weight, temperature, hematocrit, and CD4-lymphocyte count, are recorded at regularly
spaced time points, until the development of clinical AIDS. These time points, which we
denote by 0 = τ0 < τ1 < τ2 < · · · < · · · < τK , may for instance correspond to clinic visits
at which the measurements are obtained, with time defined as time since the diagnosis of
HIV infection.
Our goal will be to identify and estimate, for each treatment regime, the time-to-AIDS
distribution that would have been observed if (typically counter to fact) each study subject
had followed the AZT treatment history prescribed by the regime. We shall call each such
distribution an AZT treatment regime-specific, counterfactual, time-to-AIDS distribution.
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The treatment regimes we study need not be static. A treatment regime is a rule that
assigns to each possible covariate history through time τk, an AZT dosage rate ak to be
taken in the interval (τk, τk+1]. A simple example of a treatment regime is “take an AZT
dosage ak of 1, 000 milligrams of AZT daily in the interval (τk, τk+1] if the hematocrit
measured at τk exceeds 30; otherwise take no AZT in the interval”.
Our interest in AZT treatment regime-specific, counterfactual time-to-AIDS distribu-
tions is based on the following considerations. Suppose, after the completion of the study,
a further individual with newly diagnosed HIV infection, whom we shall call “the infected
subject”, wishes to use the data from the completed study to select the AZT dosage sched-
ule that will maximize his expected or median number of years of AIDS-free survival.
If the “infected subject” is considered exchangeable with the subjects in the trial, then
he would wish to follow the AZT treatment regime whose regime-specific, counterfactual
time-to-AIDS distribution has the largest expected or median value.
In Section 3 we show that the AZT treatment regime-specific, counterfactual time-to-
AIDS distributions are identified from the observed data under the assumption that the
investigator has succeeded in recording sufficient data on the history of all covariates to
ensure that, at each time τk, given the covariate history and the AZT treatment history
up till τk, the AZT dosage rate in (τk, τk+1] is independent of the regime-specific, coun-
terfactual time-to-AIDS. Robins (1992) refers to this assumption as the assumption of no
unmeasured confounding factors. In other words, under this assumption at each time point
the treatment can be viewed as depending only on recorded information up till that point
and external factors that are not predictive of (counterfactual) survival.
In Section 4 we introduce structural nested failure time models (SNFTM). An SNFTM
models the magnitude of the causal effect of a (final) blip of AZT treatment in the interval
(τk, τk+1] on time-to-AIDS, as a function of past AZT and covariate history. We show that,
under the assumption of no unmeasured confounding, the null hypothesis of no causal effect
of AZT on time-to-AIDS is equivalent to the null hypothesis that the parameter vector of
any SNFTM is 0.
The term “structural” in SNFTM derives terminology used in the social science and
econometric literature (e.g. Rubin (1978)). Our models are “structural”, because they
directly model regime-specific, counterfactual time-to-AIDS distributions. In Sections 6
and 7 we discuss two different methods to fit SNFTMs and to use them for inference.
In Section 6 we show that, under the assumption of no unmeasured confounding,
SNFTMs can be understood as a component of a particular reparameterization of the
joint distribution of the observables. We use this reparameterization to develop likelihood-
based tests of the causal null hypothesis of no effect of AZT-exposure on time-to-AIDS.
We also show how to estimate the AZT-treatment regime-specific, counterfactual time-
to-AIDS distributions, in the case that the null hypothesis of no causal effect of AZT on
time-to-AIDS is rejected.
In Section 7 we present an alternative, semiparametric approach to test the null hypoth-
esis of no treatment effect and to estimate the parameters in an SNFTM. This approach,
G–estimation, has the advantage of avoiding for parameterization of the distributions ap-
pearing in the likelihood-based approach of Section 6 (e.g. the conditional distributions of
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covariates given past treatment- and covariate history). Instead G–estimation uses a model
for the SNFTM and for the conditional distribution of treatment given past treatment- and
covariate history. Tests and estimators based on G-estimation have the additional advan-
tage that they can often be calculated with standard software.
2 Formalization of the problem
We fix a discrete time frame τ0 = 0 < τ1 < τ2 < . . . < τK throughout the paper, where τ0
is the time of enrollment in the study (and possibly also initiation of treatment), τ1, τ2, . . .
are the times of the clinic visits, and τK can be the time of the last clinic visit, or can be
chosen past the upper support point of the time-to-AIDS distribution. For simplicity the
times of the clinic visits are assumed to be the same for all patients (as long as they are
alive).
At each time point τk we measure a covariate vector Lk for each patient, where L0 may
also contain time-independent covariates and information collected before time τ0, and we
register the treatment given in the interval (τk, τk+1] in a variable Ak, for instance the
AZT dosage, assumed constant during the interval. Besides covariates Lk and treatments
Ak, we observe for each person a positive time T , for instance the time from enrollment
to the development of clinical AIDS. Thus the data observed on one person is a vector
(LK , AK , T ), where, for each k = 0, 1, . . . , K,
Lk = (L0, L1, . . . , Lk),
Ak = (A0, A1, . . . , Ak).
For time instances τk > T the values Lk and Ak may be interpreted to be empty. For
simplicity we assume that the variables Lk and Ak take their values in countable sets,
denoted by Lk and Ak. The total set of observations are a sample of n independent and
identically distributed (i.i.d.) observations from the distribution of the random vector
(LK , AK , T ).
As is clear from the preceding display we use the overline notation to denote a “cu-
mulative vector”. For simplicity of notation, it will be understood that whenever two
expressions such as lk and lk−1 occur together, then lk−1 is the initial part of lk.
A “treatment regime” is a prescription for the treatment dosages fixed at the times τk,
where at each time instant the prescribed treatment may depend on the observed covariate
history until this time. We make this precise in the following definition.
Definition 2.1 (treatment regimes). A treatment regime g is a vector g = (g0, . . . , gK) of
functions gk : L0 × · · · × Lk → Ak.
The value ak = gk(lk) of the kth coordinate of the treatment regime g at covariate lk
is interpreted as the dosage prescribed by treatment regime g in the interval (τk, τk+1] to a
patient with covariate history lk following this regime (up to time τk). The treatment at
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time τk may depend on the full covariate history lk = (l0, . . . , lk) until time τk, not just on
lk. We define maps gk : L0 × · · · × Lk → A0 × · · · × Ak by
gk(lk) =
(
g0(l0), g1(l1), . . . , gk(lk)
)
.
To alleviate notation we may drop the subscripts k or the overline in gk or gk if the value of
k is clear from the context. In particular g(lK) = g(lK) = gK(lK) are equivalent notations
for the complete treatment history.
We wish to study the effect of treatment using the observed data. Depending on this
data not all treatment regimes may be accessible to analysis. We call a treatment regime
“evaluable” (relative to the distribution of the data vector (LK , AK , T )) if whenever the
regime was followed until some time τk by some positive fraction of the population, then
it is also followed in the interval (τk, τk+1].
Definition 2.2 (evaluable treatment regimes). A treatment regime g is called evaluable if
for each k and each lk ∈ Lk,
P
(
Lk = lk, Ak−1 = g
(
lk−1
)
, T > τk
)
> 0⇒ P (Lk = lk, Ak = g (lk) , T > τk) > 0.
Next we introduce counterfactual variables. These will be instrumental both to express
the aims of the statistical analysis, and to formulate our assumptions. In our mathematical
model the counterfactual variables are ordinary random variables T g, one for each treat-
ment regime g, that are assumed to be defined on the same probability space as the data
vector (LK , AK , T ). The variable T
g should be thought of as a patient’s time to clinical
AIDS had she been treated according to treatment regime g. Because in actual fact the
patient receives treatment A¯K (resulting in time to aids T ), the variable T
g is “counter to
fact”. However, it gives a useful notation to express the distribution of interest, and will
be related to the observable variables by two assumptions.
Counterfactual variables referring to different subjects are assumed independent (cf.
Rubin (1978)), and hence we can formulate our set-up in terms of the set of random
variables (T g, T, LK , AK) referring to one person. We shall not be interested in the joint
distribution of counterfactual variables corresponding to different treatment regimes. We
also do not need counterfactual versions of the covariates or treatments.
We describe the aims of the statistical analysis in terms of the counterfactual variables.
The G–null hypothesis of no effect of AZT on time-to-AIDS is the hypothesis that
P (T g1 > t) = P (T g2 > t) for all treatment regimes g1 and g2.
In Section 6 we derive fully parametric likelihood-based tests of this G–null hypothesis
based on a random sample from the distribution of the observables
(
LK , AK , T
)
, and a
parametric model for their joint distribution. In Section 7 we develop an alternative,
semi-parametric procedure with the same aim.
If the G–null hypothesis is rejected, then the next goal is to identify and estimate,
for each treatment regime g, the survival curve t 7→ P (T g > t), i.e. the survival curve
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that would have been observed had a subject followed regime g. Specifically, if our in-
fected subject outside of the study mentioned in the introduction wishes to maximize
his expected years of AIDS-free survival, he would follow the regime g that maximized
ET g =
∫∞
0
P (T g > t) dt. Inference regarding the distribution of counterfactual variables
is referred to as causal inference, as the outcomes T g are interpreted as being the effect of
the treatment regime g.
Clearly it is impossible to make inference about the counterfactual survival distributions
P (T g > t) based on the observed data unless the variables T g and (LK , AK , T ) are related.
The assumed coupling of these variables on a given underlying probability space allows to
make the following assumptions relating counterfactual and factual variables.
Assumption 2.3 (consistency). For any treatment regime g, lk ∈ Lk and t ∈ (τk, τk+1],{
T g > t, Lk = lk, Ak = g
(
lk
)
, T > τk
}
=
{
T > t, Lk = lk, Ak = g
(
lk
)
, T > τk
}
.
Assumption 2.4 (no unmeasured confounding). For any treatment regime g, for any
time τk and for any lk ∈ Lk,
Ak⊥⊥T g|Lk = lk, Ak−1 = g
(
lk−1
)
.
Here the notation X⊥⊥Y |Z = z, borrowed from Dawid (1979), means that the random
variabless X and Y are conditionally independent given the event Z = z.
The consistency assumption, Assumption 2.3, couples the true and counterfactual sur-
vival times T and T g by merely stating that if until some time τk a patient is treated
exactly as prescribed by regime g, then she would die at some time in the interval (τk, τk+1]
under regime g if and only if she actually died at the same time. This implies in particular
that if all patients were treated according to a predetermined treatment regime, then coun-
terfactual and actual survival times coincide. This is the customary situation in clinical
trials, but may fail to be the case in an observational study.
The assumption of no unmeasured confounding, Assumption 2.4, can be expected to
hold if the observed covariate history LK contains sufficient information, so that at each
time τk the treatment Ak can be assumed to depend on the covariate history Lk of a
patient up till that time and no other relevant information. The assumption would for
instance hold if at each time τk the treatment in the interval (τk, τk+1] is assigned through
randomization within fixed levels of equal covariates Lk and earlier treatments.
More specifically, in our AIDS example Assumption 2.4 may be expected to hold if
the following information is recorded in Lk: all risk factors (i.e. predictors) of regime-
specific, counterfactual time-to-AIDS, other than prior AZT-history Ak−1, that are used
by physicians and patients to determine the dose Ak of AZT in (τk, τk+1]. Then, given
Lk and Ak−1 = g
(
Lk−1
)
, the treatment Ak in the interval (τk, τk+1] may be thought of
as depending only on external factors unrelated to the patient’s prognosis regarding time-
to-AIDS, and hence as being independent of T g. For example, since it is known that
physicians tend to prescribe AZT to subjects with low CD4-counts and a low CD4-count is
an independent predictor of time-to-AIDS, the assumption of no unmeasured confounding
would be false if Lk does not contain CD4-count history.
It is a basic objective of epidemiologists conducting an observational study to collect
data on a sufficient number of covariates to ensure that Assumption 2.4 will be true. In
this paper, we assume this objective has been realized, while recognizing that, in practice,
this may only approximately be the case.
3 G–computation
We are interested in the distribution of the counterfactual, and hence unobservable, vari-
ables T g, as they indicate the success or failure from applying the treatment regime g. In
this section we show that, under Assumptions 2.3 and 2.4, the distribution of T g is identi-
fiable from the distribution of the observed data
(
LK , AK , T
)
for each evaluable treatment
regime g. As a consequence, given a random sample from the latter distribution, the
distribution of T g is estimable, in principle.
In fact, the following G–computation formula gives an explicit expression for P (T g > t),
as well as several conditional survival functions, in terms of the distribution of the data(
LK , AK , T
)
.
Theorem 3.1 (G–computation-formula). Suppose that Assumptions 2.4 (no unmeasured
confounding) and 2.3 (consistency) hold, and that g is an evaluable treatment regime. Then
for any t > 0, with p defined by τp < t ≤ τp+1,
P (T g > t) =
∑
l0
· · ·
∑
lp−1
∑
lp
[
P
(
T > t|Lp = lp, Ap = g
(
lp
)
, T > τp
)
×
p∏
m=0
{
P
(
T > τm|Lm−1 = lm−1, Am−1 = g
(
lm−1
)
, T > τm−1
)
×P
(
Lm = lm|Lm−1 = lm−1, Am−1 = g
(
lm−1
)
, T > τm
)}]
.
In the preceding theorem we interpret variables indexed by−1 as not present, and events
concerning only such variables as being empty. For instance, the conditional probability
P
(
Lm = lm|Lm−1 = lm−1, Am−1 = g
(
lm−1
)
, T > τm
)
is to be read as the probability
P (L0 = l0) when m = 0.
All conditional probabilities on the right side concern observable variables. Hence the
theorem gives an explicit description of the survival function of the counterfactual variable
T g in terms of the distribution of the data (LK , AK , T ).
It is instructive to evaluate the formula in the simple case that K = 1, when there
exists only one treatment A0 applied in the single interval (0, τ1]. Then the G–computation
formula yields, for t > 0,
P (T g > t) =
∑
l0
P
(
T > t|L0 = l0, A0 = g(l0)
)
P (L0 = l0).
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This shows that in general the distribution of the counterfactual variable T g differs from
the distribution of T , which can be written in the form
P (T > t) =
∑
l0
P
(
T > t|L0 = l0
)
P (L0 = l0).
This difference is not too surprising, because the variable T g refers to the treatment regime
g, whereas T relates to the observed outcomes under the actual treatments. Had all patients
received treatment g, then the two distributions would coincide. More notable is the
difference between the conditional distribution of T given A0 = a0 and the distribution of
T g for the fixed treatment regime g that assigns all patients to treatment a0, i.e. g(l0) = a0.
These two survival distributions can be written
P (T a0 > t) =
∑
l0
P
(
T > t|L0 = l0, A0 = a0
)
P (L0 = l0),
P
(
T > t|A0 = a0
)
=
∑
l0
P
(
T > t|L0 = l0, A0 = a0
)
P
(
L0 = l0|A0 = a0
)
.
The conditional distribution of T given A0 = a0 is estimable, in principle, by taking
only those patients into account who happened to receive treatment a0. The outcome
distribution of this subset of patients may however be different from the distribution of
the counterfactual variable T a0 , as a result of “selection bias”. In the actual world some
patients may be assigned other treatments than a0, where the assignment A0 may correlate
with the covariate variable L0. Therefore, the conditional and unconditional distributions
of L0 given A0 may differ, and consequently so may the right hand sides of the display. It
is the counterfactual survival function t 7→ P (T a0 > t) that is the relevant one to judge
the causal effect of treatment a0. Randomization of treatment over patients within fixed
levels of the covariate would have made L0 and A0 independent, and the difference would
disappear. The protocol of a controlled experiment may include such randomization, but
in a observational study it cannot be taken for granted. The G–computation formula
then shows, under some assumptions, how we can still compute the relevant outcome
distributions from the observed data distribution.
We can make further comparisons after deriving a similar representation for conditional
probabilities involving the counterfactual variables.
Theorem 3.2 (G–computation-formula). Under the assumptions of Theorem 2.4, for any
k ∈ {0, 1, 2, . . . , K} and any lk such that P
(
Lk = lk, Ak−1 = g
(
lk−1
)
, T > τk
)
> 0, for any
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t > τk, and with p ≥ k defined by τp < t ≤ τp+1,
P
(
T g > t|Lk = lk, Ak−1 = g
(
lk−1
)
, T > τk
)
=
∑
lk+1
· · ·
∑
lp−1
∑
lp
[
P
(
T > t|Lp = lp, Ap = g
(
lp
)
, T > τp
)
×
p∏
m=k+1
{
P
(
T > τm|Lm−1 = lm−1, Am−1 = g
(
lm−1
)
, T > τm−1
)
×P
(
Lm = lm|Lm−1 = lm−1, Am−1 = g
(
lm−1
)
, T > τm
)}]
. (1)
Again variables indexed by −1 should be read as not being present. Furthermore, a
repeated summation of the form
∑
lk+1
· · ·∑lp ak,p(lk, lk+1, . . . , lp) is considered to be the
single term ak,k(lk) if k = p, whereas the product
∏p
k+1 is to be read as 1 in this case. The
summation may be restricted to terms whose conditioning events have positive probability.
Again we may evaluate this formula in the simple case of a single treatment interval.
Then the formula in the preceding theorem (with k = 0 = p,K = 1) reduces to
P
(
T g > t|L0 = l0
)
= P
(
T > t|L0 = l0, A0 = g(l0)
)
.
The right side is precisely the conditional distribution of the actual survival time for a
subject with covariate l0 following the treatment regime g. Intuitively, the conditional
probabilities P
(
T > t|L0 = l0, A0 = g(l0)
)
are the correct ones for evaluating the quality of
treatment g for a subject with covariate value l0, and the equality in the preceding display
is actually a direct consequence of the Assumptions 2.3 and 2.4 relating the counterfactual
and factual survival times. (We may add A0 = g(l0) in the conditioning event on the left
by Assumption 2.4, and next use Assumption 2.3 to see that T g may be replaced by T .)
Henceforth, we shall denote the right side of (1) by slk,g (t). For k = −1 this reduces
to the right side in Theorem 3.1, and we write it as sg(t), interpreting l−1 as empty. Then
Theorems 3.1-3.2 can be reformulated as saying that under Assumptions 2.3 (consistency)
and 2.4 (no unmeasured confounding), for every evaluable treatment regime g,
P (T g > t) = sg(t)
and, for every k = 0, 1, . . . , K,
P
(
T g > t|Lk = lk, Ak−1 = g
(
lk−1
)
, T > τk
)
= slk,g(t).
These functions are survival functions of distributions that concentrate on (τk,∞).
Inspection of the G–computation formula shows that slk,g is a (complicated) function
of the distribution of the data vector
(
LK , AK , T
)
and depends on this distribution only
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through the conditional distributions of the covariates and the survival time given the past,
given by
P
(
Lm = lm|Lm−1 = lm−1, Am−1 = am−1, T > τm
)
, (2)
and
P
(
T > t|Lm−1 = lm−1, Am−1 = am−1, T > τm−1
)
. (3)
In particular, the functions sg,lk do not depend on conditional laws of the treatment vari-
ables Am given the past.
Proof of Theorems 3.1 and 3.2. We prove Theorems 3.1 and 3.2 by backward induc-
tion on k, for fixed t (and hence also fixed p). Formula (1) with k = −1 can be read as the
formula given by Theorem 3.1, so we restrict to proving (1).
For k = p the left side of (1) is equal to
P
(
T g > t|Lp = lp, Ap−1 = g
(
lp−1
)
, T > τp
)
= P
(
T g > t|Lp = lp, Ap = g
(
lp
)
, T > τp
)
= P
(
T > t|Lp = lp, Ap = g
(
lp
)
, T > τp
)
,
where in the first equality we can add Ap = gp
(
lp
)
in the conditioning event by Assump-
tion 2.4 of no unmeasured confounding, and in the second equality we can replace the event
T g > t by the event T > t, because of the Assumption 2.3 of consistency.
The induction step is proved by similar arguments. Supposing that (1) holds for k ≤ p,
we shall deduce that it also holds for k − 1. We have
P
(
T g > t|Lk−1 = lk−1, Ak−2 = g
(
lk−2
)
, T > τk−1
)
= P
(
T g > t|Lk−1 = lk−1, Ak−1 = g
(
lk−1
)
, T > τk−1
)
= P
(
T g > τk|Lk−1 = lk−1, Ak−1 = g
(
lk−1
)
, T > τk−1
)
×P (T g > t|Lk−1 = lk−1, Ak−1 = g (lk−1) , T > τk−1, T g > τk) .
The first equality follows by the assumption of no unmeasured confounding, while the
second follows by conditioning on the event T g > τk, where we note that t > τk, because
t > τp ≥ τk. By the consistency assumption we can replace the event T g > τk by the
event T > τk without changing the events or probabilities. Next we can rewrite the second
probability as a sum by conditioning on the variable Lk, to obtain that the preceding
display is equal to∑
lk
[
P
(
T > τk|Lk−1 = lk−1, Ak−1 = g
(
lk−1
)
, T > τk−1
)
×P (T g > t|Lk = lk, Ak−1 = g (lk−1) , T > τk) ]
×P (Lk = lk|Lk−1 = lk−1, Ak−1 = g (lk−1) , T > τk) .
Finally we replace the probability involving the counterfactual variable T g by the right
side of (1), which is permitted in view of the induction hypothesis. This yields the right
side of (1) for k − 1, and concludes the induction step. ✷
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4 Reparameterization
To investigate the effect of a given treatment regime g on survival, it suffices to know
the conditional distributions given in (2) and (3). Given these distributions we can com-
pute the counterfactual survival functions by using the G–computation formula, given by
Theorem 3.1.
Because carrying out this computation may be a formidable task, we may perform the
calculation by simulation methods, rather than by analytical calculation. Robins (1986,
1987, 1988) provides a Monte Carlo algorithm, called the “Monte Carlo G–computation
algorithm”, for evaluating the functions sg that satisfactorily resolves potential difficulties
with the analytical computation. We refer the reader to these papers for further discussion.
A difficulty is that the distributions in (2) and (3) will typically be unknown and must
be estimated from the data. One possibility is to specify models for (2) and (3), for instance
logistic or Cox models, and next estimate the unknown parameters from the data. The
function sg can then be estimated using the Monte Carlo G–computation algorithm with
model derived estimates. Robins (1986, 1987) provides several worked examples of this
approach.
This approach has a number of unattractive features. Estimation of the function sg
according to the preceding scheme and without confidence intervals, may be feasible, but
testing whether treatment affects the outcome is complicated. The models used to specify
sg will usually be rough approximations, and the null hypothesis of no treatment effect will
be a complex function of all parameters. Standard statistical software may not apply, and
in large datasets the null hypothesis will usually be rejected, just because of model misspec-
ification (cf. Robins (1986, 1987, 1988, 1989)). In this paper we take a different approach,
based on a reparameterization of the joint distribution of the observations
(
LK , AK , T
)
using structural nested failure time models (SNFTM).
SNFTMs are models for the causal effect of skipping a “last” treatment dose given the
past, thus reverting to the “baseline treatment”. To make this precise, suppose that there
is a certain baseline treatment regime, which we shall refer to as “no treatment”. This
could for instance be “zero medication”, and consequently we shall let a zero in the sets
Ak of treatment dosages refer to treatment under the baseline treatment regime.
At any time point τk a doctor could switch a patient to the baseline regime, at least
conceptually, and leave her there. Let
(
ak, 0
)
be an abbreviation for the treatment regime
g = (a0, . . . , ak, 0, . . . , 0), i.e. the mth coordinate function of g is given by
gm
(
lm
)
=
{
am for any value of the covariate vector lm if m ≤ k,
0 if m > k.
Henceforth, we shall always assume that Assumptions 2.3 (consistency) and 2.4 (no un-
measured confounding) are satisfied. Then, by Theorem 3.1, if the treatment regime (ak, 0)
is evaluable, the function
t 7→ slk,(ak,0)(t)
(by definition the right side of (1) with g = (ak, 0)) is the conditional survival function of the
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counterfactual survival time T (ak,0) given the treatment- and covariate history
(
lk, ak−1
)
up to time τk, and given that T
(ak,0) > τk. Define “shift-functions” γ by
γlk ,ak(t) = s
−1
lk,(ak−1,0)
◦ slk,(ak,0)(t), (4)
where the inverse s−1 is the quantile function of the corresponding survival function.
The functions γ map percentiles of the distribution of the random variable T (ak,0) into
those of the distribution of the random variable T (ak−1,0),
slk,(ak−1,0) ◦ γlk,ak = slk,(ak,0). (5)
The functions γ thus measure the effect of skipping the “last” treatment dose ak given
the covariate and treatment history (lk, ak−1). We assume that the survival functions are
continuous and strictly decreasing, so that (4) and (5) give equivalent definitions.
If the “last treatment” ak has no effect, then the functions slk,(ak−1,0) and slk,(ak ,0) are
identical, and the function γlk,ak is the identity function. More generally, the function γlk,ak
can be seen to measure the effect of the treatment ak given in [τk, τk+1) on (counterfactual)
survival. This is illustrated in Figure 1.
0
1
τk tγlk,ak(t)
slk,(ak−1,0)
slk ,(ak,0)
Figure 1: Illustration of the shift-function γ. In this picture the function slk ,(ak−1,0) lies to
the left of the function slk,(ak,0), indicating that skipping the treatment ak decreases survival
for patients with covariate and treatment history (lk, ak−1). In this case the function γlk,ak
is below the identity.
Conversely, if the shift function γlk,ak is equal to the identity function, then the distri-
bution of the counterfactual variables T (ak ,0) and T (ak−1,0) coincide for patients with past
covariate- and treatment history lk and ak−1. This suggests that, if γlk,ak is the identity
function for all values of lk, ak and k, then treatment does not affect the outcome of inter-
est: skipping the last treatment does not affect the outcome of interest, next skipping the
second-last treatment does not affect the outcome of interest, etcetera.
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For a rigorous proof of this conclusion it is necessary that sufficiently many treatment
regimes are evaluable, because the functions slk,g (defined in terms of the distribution
of the observable data by the right side of (1)) are equal to the counterfactual survival
distributions only if the treatment regime g is evaluable. For instance, the treatment regime
g =
(
ak, 0
)
need not be evaluable for all ak and hence the distributions of the counterfactual
variables T (ak,0) and/or T (ak−1,0) may not be identifiable from the observed data. To
overcome this difficulty we assume that the baseline treatment regime 0 is “admissible”. A
treatment regime is called “admissible” if in every situation there is a positive probability
for this regime to be implemented in the next step. As applied to the baseline regime 0,
this property takes the form of the following assumption.
Assumption 4.1 (admissible baseline treatment regime). For each k, each lk ∈ Lk and
each ak−1 ∈ Ak−1,
P
(
Lk = lk, Ak−1 = ak−1, T > τk
)
> 0⇒ P (Lk = lk, Ak−1 = ak−1, Ak = 0, T > τk) > 0.
Under this assumption the shift functions γlk,ak are identifiable for all values of (k, lk, ak)
with P
(
Lk = lk, Ak = ak, T > τk
)
> 0, and fully characterize the potential effect of any
treatment regime. This is the content of the following theorem, whose proof is deferred
to Appendix A. (As shown in Lok (2001, Section 2.12), Assumption 4.1 can be avoided
if one allows 0 to be a so-called admissible baseline course of treatment, which may not
only depend on past covariate- but also on past treatment history. Some admissible base-
line course of treatment, which has a positive probability of occurring after any observed
treatment- and covariate history, always exists.)
Theorem 4.2 Under Assumptions 2.4 (no unmeasured confounding), 2.3 (consistency)
and 4.1 (admissible baseline treatment regime), the distribution of T g is the same under
all evaluable treatment regimes g if and only if the shift-function γlk,ak is the identity for
all (k, lk, ak) with P
(
Lk = lk, Ak = ak, T > τk
)
> 0.
It follows that the functions γlk,ak characterize the null hypothesis of no treatment
effect. Because they also possess an easy interpretation in terms of the effect of a “last
blip” of treatment, it is attractive to model these functions rather than the set of conditional
distributions in (2) and (3). A structural nested failure time model is a parametrized family
of functions used to model the functions γlk ,ak . Each of the model functions is an increasing
function on [τk,∞) (that can arise as a quantile-distribution function), with the identity
function referring to the absence of the treatment effect.
With the parameter denoted by ψ = (ψ1, ψ2, ψ3), one example of an SNFTM would be
γ
ψ
lk,ak
(t) = τk + (min {τk+1, t} − τk) eψ1ak+ψ2akak−1+ψ3aklk + (t− τk+1) 1{t>τk+1}.
If ψ = 0, then this function reduces to the identity function, indicating that the parameter
value ψ = 0 corresponds to the absence of a treatment effect. For nonzero values of ψ the
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Figure 2: Examples of shift functions. The picture shows the identity function (dashed)
and the function t 7→ τk+(min {τk+1, t} − τk) 0.5+(t− τk+1) 1{t>τk+1} for τk = 1 < τk+1 = 2,
which corresponds to decreasing survival by skipping the treatment in the interval (τk, τk+1].
model corresponds to a “change of time scale” depending on present and past treatment
(ak, ak−1) and present covariate (lk). The variable Lk might for instance be the univariate
covariate CD4 lymphocyte count at τk, and the variable Ak the AZT prescription. Then
the given model allows for interaction between CD4 lymphocyte count and treatment, and
could of course be extended with other factors. Figure 2 shows two typical functions γ
following this model.
5 Mimicking counterfactual outcomes
In the next two sections we present two methods for estimating the parameter ψ in a
structural nested failure time model. Theorem 5.1 below is basic for both methods. Con-
sider the following transformation of the observation
(
LK , AK , T
)
, using the “true” shift
functions γ (given by (4)):
T
γ
0 = γL0,A0 ◦ γL1,A1 ◦ · · · ◦ γLp(T ),Ap(T ) (T ) , (6)
where p(T ) = max {k : τk < T}. The application of the function γLp(T ),Ap(T ) to T annihilates
the effect of the last treatment Ap(T ), and each further application of a shift function
annihilates the effect of an earlier treatment. This explains the following theorem, which
is proved in Appendix B.
Theorem 5.1 (mimicking counterfactual outcomes). The variable T γ0 defined in (6) pos-
sesses survival function s0. Furthermore, for every k ≥ 0,
Ak⊥⊥T γ0 |Lk, Ak−1, T > τk. (7)
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The variable T γ0 is a (deterministic) function of the data vector
(
LK , AK , T
)
, through
the (unknown) family of shift-functions γ. If the shift functions γ would be known, then
we would be able to “mimic” the survival time without treatment by calculating the trans-
formation T γ0 . By the preceding theorem this variable is distributed according to s0 and
hence under the conditions of Theorem 3.1 possesses the same distribution as T g for g = 0,
the null treatment.
Equation (7) shows that the variable T γ0 also shares the “no unmeasured confounding”
property (Assumption 2.4) of counterfactual variables (in a slightly stronger form).
6 Maximum likelihood estimation
In this section we consider likelihood based inference for the parameter ψ in a given
SNFTM. Clearly this requires that we make the parameter ψ visible in the density of
the observation
(
LK , AK , T
)
. We first show that this can be achieved using the transfor-
mation T γ0 = T
γ
0
(
T, LK , AK
)
defined in (6), which will depend on ψ if we use a SNFTM
for γ.
Theorem 6.1 (the likelihood rewritten). Suppose that Assumption 4.1 (admissible base-
line treatment regime) holds. Suppose moreover that
(
T, LK , AK
)
has a Lebesgue density,
and that the function t 7→ s(lk,(ak,0)) (t) is continuously differentiable in t, for all lk, ak
with P
(
Lk = lk, Ak = ak, T > τk
)
> 0, with strictly negative derivative except for at most
finitely many points. Then the joint density of
(
T, L,A
)
can be rewritten as
fT,L,A
(
t, l, a
)
=
∂
∂t
t
γ
0
(
t, lp, ap
)
fT γ0
(
t
γ
0
(
t, lp, ap
))
P (L0 = l0|T γ0 = tγ0)P (A0 = a0|L0 = l0)
p∏
k=0
{
P
(
Lk = lk|Lk−1 = lk−1, Ak−1 = ak−1, T > τk, T γ0 = tγ0
)
P
(
Ak = ak|Lk = lk, Ak−1 = ak−1, T > τk
)}
,
where τp < t ≤ τp+1 and
t
γ
0
(
t, lp, ap
)
= γl0,a0 ◦ γl1,a1 ◦ · · · ◦ γlp,ap (t) .
Proof. Under the conditions of Theorem 6.1,(
T, L,A
) 7→ (T γ0 , L, A) = (tγ0 (T ) , L, A)
is a one-to-one mapping. Thus if tγ0 were continuously differentiable everywhere, then the
identity
fT,L,A
(
t, l, a
)
=
∂
∂t
t
γ
0
(
t, l, a
)
fT γ0 ,L,A
(
t
γ
0
(
t, l, a
)
, l, a
)
(8)
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would be immediate from the change of variables formula. We show that (8) holds under
the conditions of Theorem 6.1 too. Next the assertion of the theorem follows by repeated
conditioning and using Theorem 5.1.
To prove (8) in general, note that the probability space consists of countably many sets
of the form
(
LK = lK , AK = aK
)
, so that by countable additivity of measures it suffices to
prove (8) on each of these sets that has probability greater than 0. On each of these sets,
t
γ
0 is one-to-one and continuously differentiable except for at finitely many points: it is the
composition of finitely many functions γlk,ak and under the assumptions of Theorem 6.1,
γ′
lk,ak
(t) =
(
s−1
lk,(ak−1,0)
◦ slk,(ak,0)
)′
(t) =
1
s′
lk,(ak−1,0)
(
γlk,ak (t)
)s′
lk,(ak,0)
(t)
exists and is continuous except for at most finitely many t. Thus, from the change of
variables formula, equation (8) is true on each set
(
LK = lK , AK = aK
)
, as we needed to
show. ✷
Regarding the conditions of Theorem 6.1 we note that the baseline treatment regime
0 may not be constant, whence the death rate under 0 may change at the time points τm.
However, it will often be reasonable to assume differentiability of the function s(lk,(ak,0)) (t)
on all intervals (τm, τm+1).
For likelihood inference concerning the parameter ψ of an SNFTM, we shall generally
drop the factors
P
(
Ak = ak|Lk = lk, Ak−1 = ak−1
)
(9)
from the likelihood. All other terms involve ψ through T γ0 and we will need to specify
models for these terms in order to proceed, typically involving additional parameters.
Given such models we can estimate ψ by the corresponding coordinate of the maximum
likelihood estimator obtained by maximizing the likelihood over all parameters. Of course
finding this maximizer may be a formidable task.
Since the null hypothesis of no treatment effect is equivalent to the functions γlk,ak being
equal to the identity function, by Theorem 4.2, this hypothesis can be fully expressed in
the parameter ψ. For instance, we could, by convention, construct our SNFTM in such a
way that this null hypothesis is equivalent to H0 : ψ = 0. Then we can obtain a likelihood-
based test for the null hypothesis of no treatment effect using the Wald, score or likelihood
ratio test for H0 : ψ = 0.
7 G–estimation
The likelihood methods of the preceding section require the specification of models for the
conditional laws of the covariates, among others, next to a specification of an SNFTM. In
this section we present an alternative approach to testing and estimation of the parameter
in a SNFTM, called G–estimation in Robins (1998). This approach is based on models for
the conditional distributions of the treatment variables given in (9). It can be considered
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a semiparametric approach, where the parametric component refers to the laws (9) and
all other laws appearing in Theorem 6.1 form the nonparametric, unspecified component.
From a practical perspective modelling the distributions (9) is more attractive than mod-
elling the remaining laws in Theorem 6.1, as it may be expected that doctors have clear
ideas, at least qualitatively, about how they reach their decisions about treatment.
The method of G–estimation is based on the conditional independence of the “blipped-
up” variable T γ0 defined in (6) and the treatment variable Ak given the variables Lk and
Ak−1, for each k, asserted by Theorem 5.1. Consider first testing the null hypothesis
H0 : γ = γ0 for a given shift function γ0. Theorem 5.1 gives, under the null hypothesis,
that, for each k,
Ak⊥⊥T γ00 |Lk, Ak−1, T > τk. (10)
This is an assertion about the observed data vector (LK , AK , T ) only. Any test for the
validity of (10) is therefore a test for the null hypothesis H0 : γ = γ0.
In order to operationalize this idea we adopt for each k a model
Pθ
(
Ak = ak|Lk = lk, Ak−1 = ak−1, T > τk
)
for the prediction of treatment given the past, indexed by some parameter θ. Such a
model tries to explain the treatment Ak by the values of the covariates up to time τk and
the preceding treatment history. Formula (10) implies that, under the null hypothesis,
inclusion of the variable T γ00 as an extra explanatory variable is useless for the prediction
of Ak, if past covariate- and treatment information Lk and Ak−1 are known. Thus given
a term of the form αT γ00 in the prediction model with α a parameter, the true value of
α must be equal to 0, because of (10). It follows that we can test the null hypothesis
H0 : γ = γ0 by adding a term αT
γ0
0 anyway, and next test the null hypothesis H0 : α = 0
in the model indexed by the overall parameter (θ, α). Depending on the chosen types of
model such a test, for instance a Wald, score or the likelihood ratio test, can be performed
by standard statistical software.
This procedure is particularly simple for testing the null hypothesis of no treatment
effect. In view of Theorem 4.2, this is equivalent to testing whether the function γ is equal
to the identity function, i.e. we take γ0 in the preceding equal to the identity function. In
this case the variable T γ00 is equal to T , and hence the G–estimation procedure reduces
to testing the null hypothesis H0 : α = 0 in a regression model that tries to explain the
variable Ak by the variables Lk, Ak−1 and αT . The null hypothesis of no treatment effect
can be tested in this way without specifying a model for the shift function γ.
For a specific example, suppose that the treatment variables Ak are binary-valued.
Then a logistic regression model is a standard choice for modelling the probabilities (9).
We might add the variable αT γ0 to a logistic regression model to form the model
Pθ,α
(
Ak = ak|Lk, Ak−1, T > τk, T γ0
)
=
1
1 + eθ·fk(Lk,Ak−1)+αgk(T
γ
0 )
,
for given, known functions fk and gk, and unknown parameters θ and α. A test for the
null hypothesis H0 : α = 0 can be carried out by standard software for logistic regression.
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Given an SNFTM ψ 7→ γψ for the shift functions γ, indexed by a parameter ψ, we can
extend the preceding testing methods to full inference on the parameter ψ. First, we can
obtain confidence regions for ψ by inverting the tests for the null hypotheses H0 : γ = γψ
in the usual way: the value ψ belongs to the confidence region if the corresponding null
hypothesis H0 is not rejected.
A natural estimator of ψ would be the center of a confidence set, or, alternatively, a
value of ψ for which T
γψ
0 contributes the least to the prediction model for treatment given
the past. That is, the ψ for which the fitted model for
Pθ,α
(
Ak = ak|Lk, Ak−1, T > τk, αT γψ0
)
. (11)
does not include the variable T
γψ
0 , i.e. α = 0. For each given value of the parameter ψ of
the SNFTM we may obtain estimators θˆ(ψ) and αˆ(ψ) for the parameters θ and α, based
on the observations (L
i
K , A
i
K , T
i) on n persons. Then we define ψˆ as the solution of the
equation
αˆ (ψ) = 0.
If we use a logistic regression model, then the estimators θˆ and αˆ can be obtained with
standard software, for each given value of ψ. The estimator ψˆ can next be found by a grid
search method. Alternatively, we can implement a direct numerical method for estimating
ψ.
The procedures just outlined may appear a bit unusual, in view of their indirect nature.
However, in most cases they can also be interpreted in a standard way. For instance, the
procedure for estimating α for given ψ will often be equivalent to solving αˆ = αˆ (ψ) from
an estimating equation of the type
n∑
i=1
hα,ψ
(
L
i
K , A
i
K , T
i
)
= 0.
Then ψˆ satisfying αˆ
(
ψˆ
)
= 0 will satisfy the estimating equation
n∑
i=1
h0,ψˆ
(
L
i
K , A
i
K , T
i
)
= 0.
Because α(ψ0) = 0 for the true value ψ0 of ψ, the true value of ψ is a solution to the
equation
Eh0,ψ
(
LK , AK , T
)
= 0.
In other words, ψˆ will be the solution of an unbiased estimating equation, whence the
(asymptotic) properties of ψˆ can be ascertained with the usual theory for M-estimators
(e.g. Van der Vaart (1998)). For instance, we may expect the sequence
√
n
(
ψˆ − ψ) to be
asymptotically (as n→∞) normal with mean zero and variance
Eh20,ψ
(
LK , AK , T
)
(
∂
∂ψ
Eh0,ψ
(
LK , AK , T
))2 .
Lok (1991) has studied the validity of these results, and has thus justified the preceding
procedures.
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8 Summary and extensions
We have shown that the AZT treatment regime-specific, counterfactual AIDS-free survival
curves P (T g > t) are identified for all evaluable treatment regimes g if our maintained
assumption of no unmeasured confounding, Assumption 2.4, is met. This assumption
will hold if the investigator has succeeded in recording in lk data on all covariates that,
conditional on past AZT history ak−1, predict both the AZT dosage rate ak in (τk, τk+1]
and the random variables T g representing time to AIDS had, contrary to fact, all subjects
followed an AZT treatment history consistent with regime g.
Further, we have shown that, under the assumption of no unmeasured confounding,
Assumption 2.4, the shift functions γ of an SNFTM are the identity function if and only
if the G–null hypothesis of no causal effect of AZT on time to AIDS is true. We have
expressed the likelihood of the observable random variables
(
T, LK , AK
)
in terms of the
transformed random variables
(
T
γ
0 , LK , AK
)
. We then developed parametric likelihood
based tests of the hypothesis γ = id by specifying fully parametric models for the joint
distribution of
(
T, LK , AK
)
in terms of the transformed random variables
(
T
γ
0 , LK , AK
)
.
Even in the absence of censoring or missing data, a major limitation of the fully para-
metric likelihood-based tests of the null hypothesis γ = id from Section 6 is that mis-
specification of the parametric models for the distribution of Lk given Lk−1, Ak−1 and T
γ
0 ,
or for the distribution of T 0, can cause the true α-level of the test to deviate from the
nominal α-level. This limitation raised the question of whether it is possible to construct
α-level tests of the null hypothesis γ = id and of more general hypotheses concerning
γ, which are asymptotically distribution-free. A closely related question is whether there
exist n1/2-consistent asymptotically normal estimators of the parameter ψ of a correctly
specified structural nested failure time model if the joint distribution of the observables(
LK , AK , T
)
is otherwise unspecified, i.e. if the distribution of Lk given Lk−1, Ak−1 and
T
γ
0 and the distribution of the variable T
0 are left completely unspecified. In Section 7 we
showed that one only needs to specify a parametric model for the shift function γ, which
models the causal effect of one treatment dosage given the past, and a parametric model
for the distribution of actual treatment dosage given past treatment- and covariate history.
Doctors will usually have clear ideas about this latter distribution of treatment decisions.
Moreover, the doctors’ interest will often be in the causal effect of one treatment dosage
given the past.
If the null hypothesis of no treatment effect has been rejected and the parameter ψ of the
shift function γ has been estimated, one might wish to estimate the survival distribution
t 7→ P (T g > t) of the outcome under specific treatment regimes g in a way consistent
with the estimator ψˆ. This can be done by estimating the distribution of T 0 (e.g. by the
empirical distribution of T γ
ψ
0 ) and the empirical distribution of Lk given Lk−1, Ak−1 and
T
γ
0 (k = 0, . . . , K) for histories Lk−1, Ak−1 consistent with g. An approximate sample T˜
g
i
(i = 1, 2, . . .) from the distribution of T g could then be generated by using these estimated
distributions: first draw T ′0 from the distribution of T
0, then draw L′0 from the distribution
of L0 given T
γ
0 = T
′
0, then put A
′
0 = g
(
L′0
)
, then draw L′1 from the distribution of L1 given
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T
γ
0 = T
′
0, A0 = A
′
0 and L0 = L
′
0, etcetera. Finally put
T˜ g = γψˆ
L
′
K ,A
′
K
−1 ◦ . . . ◦ γψˆ
L
′
0,A
′
0
−1(
T ′0
)
.
This variable will be generated from the desired distribution.
Extensions of the results of this paper that allow for censoring and missing data are
discussed in Robins (1988, 1992, 1993, 1998), and Robins et al (1992). The extension of
G–tests and estimators to continuous Lk and Ak are discussed in Robins (1992, 1993),
Robins et al. (1992), and Gill and Robins (2001). Robins (1998) and Lok (2001) show
that the results in this paper can be extended to allow for jumps in the treatment- and
covariate processes in continuous time.
A Alternative formulation of the null hypothesis
In this appendix we prove Theorem 4.2 through two lemmas. The first lemma shows that
if all functions γ are equal to the identity function, then all survival curves P (T g > t) for
evaluable treatment regimes are the same. The second lemma shows the reverse.
Lemma A.1 Suppose that Assumptions 2.4 (no unmeasured confounding), 2.3 (consis-
tency) and 4.1 (admissible baseline treatment regime) hold. If γlk,ak is the identity function
for all k, lk ∈ Lk and ak ∈ Ak with P
(
Lk = lk, Ak = ak, T > τk
)
> 0, then all survival
curves P (T g > t) for evaluable treatment regimes g are the same.
Proof. We show that for all evaluable treatment regimes g and all lk with
P
(
Lk = lk, Ak = g
(
lk
)
, T > τk
)
> 0, the conditional distributions of the counterfactual
variables T g and T (gk−1(lk−1),0) given Lk = lk, Ak−1 = g
(
lk−1
)
, T > τk are the same, i.e.,
for t ≥ τk,
slk,g(t) = slk,(gk−1(lk−1),0)(t). (12)
For k = −1 this should be read as sg (t) = s0(t), which implies Lemma A.1.
We prove (12) by backward induction on k, for t fixed. With τp the last clinic visit
time strictly before t, we start with k = p and end with k = 0. The statement for k = −1
follows from the statement for k = 0 by summation over l0.
Basis: For k = p, by the definition of s as the right side of (1),
slp,g(t) = P
(
T > t|Lp = lp, Ap = gp
(
lp
)
, T > τp
)
= slp,(gp(lp),0)(t),
by another application of the definition of s. The right side is equal to slp,(gp−1(lp−1),0)(t)
by the assumption that the function γlp,ap with ap = gp(lp), is the identity function is the
identity.
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Induction step: we suppose that (12) is true for k ≥ 1 and establish (12) for k − 1. By
straightforward algebra using the definition of slk−1,g,
slk−1,g (t) = P
(
T > τk|Lk−1 = lk−1, Ak−1 = g
(
lk−1
)
, T > τk−1
)
∑
lk
P
(
Lk = lk|Lk−1 = lk−1, Ak−1 = g
(
lk−1
)
, T > τk
)
slk,g (t) .
Here we can replace slk ,g using the induction hypothesis, giving that the preceding display
is equal to
P
(
T > τk|Lk−1 = lk−1, Ak−1 = g
(
lk−1
)
, T > τk−1
)
∑
lk
P
(
Lk = lk|Lk−1 = lk−1, Ak−1 = g
(
lk−1
)
, T > τk
)
slk,(gk−1(lk−1),0) (t)
= slk−1,(gk−1(lk−1),0)
(t)
= slk−1,(gk−2(lk−2),0) (t) ,
where we use the definition of s in the first equality, and the assumption that γlk−1,ak−1 ,
for ak−1 = gk−1(lk−1), is the identity function in the second. ✷
Lemma A.2 Suppose that Assumptions 2.4 (no unmeasured confounding), 2.3 (consis-
tency) and 4.1 (admissible baseline treatment regime) hold. If the survival curves P (T g > t)
are the same for all evaluable treatment regimes g, then the shift function γlk,ak is the iden-
tity for all k, lk ∈ Lk and ak ∈ Ak with P
(
Lk = lk, Ak = ak, T > τk
)
> 0.
Proof. Let fixed lk, ak with P
(
Lk = lk, Ak = ak, T > τk
)
> 0 be given. To prove that
γlk ,ak is the identity we need to show that, for all t > τk,
slk,(ak,0)(t) = slk,(ak−1,0)(t). (13)
Define a treatment regime g1 by the coordinate functions g1m
(
l˜m
)
= am if l˜m is the initial
part of lk, and by g
1
m
(
l˜m
)
= 0 otherwise. Define a second treatment regime g2 by and
g2 =
(
g1k−1, 0
)
. Because of Assumption 4.1 and because P
(
Lk = lk, Ak = ak, T > τk
)
>
0, the treatment regimes g1 and g2 are evaluable. Thus, by assumption, we have that
P (T g1 > t) = P (T g2 > t), and these probabilities are given by the G–computation formula,
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given in Theorem 3.1. For the first regime this formula can be written in the form
P (T g1 > t)
=
∑
l˜0
· · ·
∑
l˜k
1
l˜k 6=lk
k∏
m=0
{
P
(
T > τm|Lm−1 = l˜m−1, Am−1 = g1
(
l˜m−1
)
, T > τm−1
)
P
(
Lm = l˜m|Lm−1 = l˜m−1, Am−1 = g1
(
l˜m−1
)
, T > τm
)}
s
l˜k ,g1
(t)
+
[ k∏
m=0
{
P
(
T > τm|Lm−1 = lm−1, Am−1 = g1
(
lm−1
)
, T > τm−1
)
P
(
Lm = lm|Lm−1 = lm−1, Am−1 = g1
(
lm−1
)
, T > τm
)}]
slk,g1(t).
A similar expression holds for the treatment regime g2. Because the regimes g1 and g2 are
constructed to be the same up to time τk−1, only the second terms of the summs differs be-
tween these two expressions. Even there, the product preceding slk,g1(t) and slk,g2(t) is the
same for g1 and g2. Moreover, this factor is strictly positive, since P
(
Lk = lk, Ak = ak, T > τk
)
>
0 by assumption. The equality of P (T g1 > t) and P (T g2 > t) therefore implies the equality
of slk,g1(t) and slk,g2(t). By construction of g
1 and g2, equation (13) and hence Lemma A.2
follow. ✷
B Mimicking counterfactual outcomes
For t > 0 define p(t) by τp(t) < t ≤ τp(t)+1, i.e. τp(t) is the last clinic visit time strictly before
t. For k ≥ 0 with k ≤ p(T ) we define a random variable by
T
γ
k = γLk,Ak ◦ · · · ◦ γLp(T ),Ap(T )(T ).
For k > p(T ) we interprete the (empty) composition of transformations on the right as the
identity and define T γk = T .
In this appendix we prove the following theorem, which generalizes the first part of The-
orem 5.1. This theorem implies the second part, since T γ0 is a function of
(
Lk−1, Ak−1, T
γ
k
)
.
Theorem B.1 For t > τk and every lk, ak with P
(
Lk = lk, Ak = ak, T > τk
)
> 0,
P
(
T
γ
k > t|Lk = lk, Ak = ak, T > τk
)
= P
(
T
γ
k > t|Lk = lk, Ak−1 = ak−1, T > τk
)
= slk,(ak−1,0)(t).
Proof. We use backward induction on k, starting with k = K and ending with k = 0.
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For k = K,
P
(
T
γ
K > t|LK = lK , AK = aK , T > τK
)
= P
(
γlK ,aK (T ) > t|LK = lK , AK = aK , T > τK
)
= P
(
T > γ−1
lK ,aK
(t)|LK = lK , AK = aK , T > τK
)
= slK ,(aK ,0)
(
γ−1
lK ,aK
(t)
)
= slK ,(aK−1,0)(t).
Here the first equality is immediate from the definition of T γK , the second follows by the
strict monotonicity of the functions γ, the third by definition of s and the last by definition
of γ.
Induction step: we show that if the theorem is true for k + 1, then it is also true for k.
Just as for k = K,
P
(
T
γ
k > t|Lk = lk, Ak = ak, T > τk
)
= P
(
T
γ
k+1 > γ
−1
lk,ak
(t)|Lk = lk, Ak = ak, T > τk
)
.
Now we distinguish two possibilities: γ−1
lk,ak
(t) ≤ τk+1 and γ−1lk,ak(t) > τk+1. In the first case,
the right side of the preceding display is equal to
P
(
T > γ−1
lk,ak
(t)|Lk = lk, Ak = ak, T > τk
)
= slk,(ak,0)
(
γ−1
lk,ak
(t)
)
= slk,(ak−1,0)(t),
where the first equality holds because for s ∈ (τk, τk+1] we have that
{
T
γ
k+1 > s
}
= {T > s}
by the construction of T γk+1, and the last equality holds by the definition of γ. In the second
possibility, i.e. if γ−1
lk ,ak
(t) > τk+1,
P
(
T
γ
k+1 > γ
−1
lk,ak
(t)|Lk = lk, Ak = ak, T > τk
)
= P
(
T
γ
k+1 > τk+1|Lk = lk, Ak = ak, T > τk
)
P
(
T
γ
k+1 > γ
−1
lk,ak
(t)|Lk = lk, Ak = ak, T > τk, T γk+1 > τk+1
)
= P
(
T > τk+1|Lk = lk, Ak = ak, T > τk
)
∑
lk+1
{
P
(
Lk=1 = lk+1|Lk = lk, Ak = ak, T > τk+1
)
P
(
T
γ
k+1 > γ
−1
lk,ak
(t)|Lk+1 = lk+1, Ak = ak, T > τk+1
)}
= P
(
T > τk+1|Lk = lk, Ak = ak, T > τk
)
∑
lk+1
{
P
(
Lk=1 = lk+1|Lk = lk, Ak = ak, T > τk+1
)
slk+1,(ak,0)
(
γ−1
lk,ak
(t)
)}
= P
(
T > τk+1|Lk = lk, Ak = ak, T > τk
)
∑
lk+1
{
P
(
Lk=1 = lk+1|Lk = lk, Ak = ak, T > τk+1
)
slk+1,(ak−1,0) (t)
}
= slk,(ak−1,0)(t),
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where in the first step we condition on T γk+1 > τk+1, in the second we use that
{
T
γ
k+1 > τk+1
}
=
{T > τk+1} and we condition on Lk+1, the fourth is the induction step, the fifth follows
from the definition of γ and the last from the definition of slk,(ak−1,0). ✷
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